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Abstract
Genistein [4′,5,7-trihydroxyisoﬂavone or 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one] is a
natural isoﬂavone occurring in many plants known to possess various biological activities, ranging from
phyto-oestrogenic to antioxidative actions. Recent studies indicated that this isoﬂavone can also be
considered as a drug for as yet untreatable genetic diseases. In the present review, we discuss a plausible
use of genistein in treatment of two genetic disorders: CF (cystic ﬁbrosis) and MPS (mucopolysaccharidosis).
Although various biological actions of genistein are employed in these two cases, in vitro studies, tests on
animal models and pilot clinical trials suggest that this plant-derived compound might be a real hope for
patients suffering from severe inherited disorders with relatively complicated pathomechanisms, including
those affecting the central nervous system.
Introduction: genistein as a
multifunctional bioactive
compound
Genistein (Figure 1) is a common name of 5,7-dihydroxy-
3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one. Since this
compound belongs to the group of isoflavones, heterocyclic
polyphenols that naturally occur in plants, it is also
called 4′,5,7-trihydroxyisoflavone [1]. In fact, some plants,
including soya, are especially rich in genistein, although in
the natural form it occurs as a glycoside called genistin
(Figure 1), rather than as an aglycone (for a review, see
[2]).
There have been many biological functions of genistein
reported to date. Among them, phyto-oestrogenic, anti-
oxidant and tyrosine kinase inhibitor activities are the
most intensively studied (for reviews, see [1,3]). Since these
activities, although broad, were described as relatively weak,
for a long time genistein has generally been considered as
an auxiliary medicine, used in supportive treatment, rather
than as a main therapeutic. However, its low toxicity [4] and
undoubtedly significant (although not dramatic) biological
effects [3] have encouraged studies in which it has been
tested as a potential protective and/or therapeutic agent in
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a variety of disorders, including cancer [5–7], cardiovascular
diseases [8,9] and menopausal symptoms [10,11]. Moreover,
it has been discovered that genistein also has other biological
activities, therefore researchers have started to investigate
whether this isoflavone might be used in the treatment of
other diseases. One example is its antimicrobial potential
[12,13], and thus a possible use of genistein is in the treatment
of bacterial infections, which is especially important in the
current antibiotic crisis caused by the rapid appearance of
multidrug-resistant pathogenic bacteria. Since this aspect has
been reviewed previously [14], we will not focus on it in
the present review. On the other hand, another therapeutic
aspect of genistein is considered, namely recent studies have
suggested that genistein may be a drug for treatment of
some genetic diseases. Therefore this apparently unexpected
medical role of genistein is highlighted in the present
review.
Genistein as a potential drug in CF (cystic
ﬁbrosis)
CF is themost common fatal genetic disease in populations of
the U.S.A. and Europe. In these populations, the frequency
of this disorder is higher than 1 per 3000 live births, with a
carrier frequency of approx. 1 in 25 among Caucasians (for
recent reviews and commentaries, see [15–17]).Despite recent
achievements in management of symptoms and improvement
of life expectancy of patients, CF is still a fatal disease, with an
average lifespan in the U.S.A. and Europe still below 40 years
[16]. The main clinical problem occurring in CF is chronic
inflammation of airways, caused by frequent and severe
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Figure 1 Genistein and its glycoside, genistin
bacterial infections. This leads to the progressive suppurative
pulmonary disease, which results in airway obstruction,
destruction and respiratory failure [16]. At later stages of
the disease, airway inflammation can be associated with a
systemic inflammatory response. Although the lung disease is
not the only symptomofCFpatients (for example, pancreatic
dysfunction, elevated sweat electrolytes and male infertility
are also common in these patients), the chronic pulmonary
dysfunction is the main cause of morbidity and mortality
[15,16].
The clinical problems in CF arise from dysfunction of
a single gene. CF is a monogenic disease, inherited in an
autosomal recessive manner [15–17]. The gene affected in
patients suffering from this disease is CFTR, which encodes
the CF transmembrane conductance regulator protein. The
CFTR protein functions as an epithelial Cl− channel, whose
activity is regulated by cAMP-dependent protein kinase A
and ATP. In a lack or decreased activity of CFTR, the trans-
port of Cl− ions is impaired, which results in dehydration of
endobronchial secretions and cripples mucociliary clearance
[15,16]. Under such conditions, airways may be obstructed,
and bacterial cells, which normally should be eliminated
from the lung, remain in the pulmonary system causing
infection. Moreover, abnormal airway surface liquid volume,
resulting from impaired electrolyte transport, causes further
problems with bacterial clearance, increasing probability of
severe infections [16].
Although several hundred mutations in the CFTR gene
have been described to date [15], between 70 and 90% of CF
patients (depending on population) bear the most frequent
defective allele of this gene, calledF508. Thismutation leads
to a deletion of a phenylalanine residue at position 508 in the
1480-amino-acid polypeptide, which has two dramatic effects
on the protein properties. First, the product of the mutant
allele has severe problems with proper folding. This causes
its recognition by the ERQC (endoplasmic reticulum quality
control) system, and exposition to proteolytic degradation.
As a consequence, little, if any,F508 CFTR protein reaches
the cellular membrane, the normal compartment of wild-type
CFTR function. Secondly, the activity of F508 CFTR as a
Cl− ion channel is severely impaired. Therefore the mutated
protein is not able to both reach its proper localization in the
cells and perform its biochemical function [15].
The frequency of the F508 allele and mechanisms of
dysfunction of its product encouraged researchers to look
for potential pharmaceuticals that might restore, at least
partially, the proper localization and biochemical function
of the mutant protein. Among other strategies (reviewed
recently in [18]), the use of two novel classes of drugs appears
to be especially promising.
The first class encompasses compounds called ‘correctors’
that may allow the mutant CFTR protein to bypass ERQC
and reach the cellular membrane. Thus any residual activity
of the properly located protein may cause more or less
efficient transport of Cl− ions, which should significantly
improve functioning of affected tissues and organs. Different
chemicals, including 4-phenylbutyrate, curcumin and an
analogue of sildenafil, are currently tested for their functions
as correctors of the F508 CFTR protein [18].
‘Potentiators’ are the second class of putative drugs for
CF patients. These compounds can enhance residual activity
of the properly located mutant protein, perhaps by acting
as small molecular chaperones [18]. Genistein is one of such
chemicals. This isoflavone can enhance the Cl− ion channel
activity of not only F508 CFTR [19], but also the product
of another CFTR allele, G551D (present in 2–6% of CF
patients [18]), which may be especially amenable to this kind
of treatment as it reaches the plasma membrane as a mature
protein, but has severely impaired biochemical function [20].
It appears that the action of genistein on CFTR is direct
[21,22].
Although several other potentiators ofF508 CFTRwere
found [23,24], genistein is still one of the most efficient
activators of the mutant protein, and, because of its low
toxicity [4], it can be placed among the best candidates for
a CF therapeutic. In fact, genistein has been demonstrated
to be more effective in partial restoration of the F508
CFTR activity than other potentiators, including scopoletin,
isopsoralen, osthole, imperatorin, praeruptorin A andUCCF-
029 (7,8-benzoflavone) [23,24].
Interestingly, recent studies on themechanismof genistein-
mediated potentiation of F508 CFTR revealed that this
isoflavone acts not only by Cl− channel gating. Moderate
concentrations of genistein augmentedCFTRmaturation and
increased its localization to the cell surface [25]. These results
indicate that genisteinmay be an evenmore potent drug in the
treatment of CF than suggested previously, as it may enhance
expression, proper localization and activity of the mutant
protein.
The encouraging results of pre-clinical studies with
genistein provide a basis for clinical trials withCF patients. In
fact, the Phase II clinical trial with a combined treatment (4-
phenylbutyrate and genistein) of CF patients with theF508
mutation has commenced [18].
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Genistein as an experimental drug in
Sanﬁlippo disease (mucopolysaccharidosis
type III) and a potential therapeutic agent
for other LSDs (lysosomal storage
diseases)
LSDs are inherited metabolic disorders caused by dysfunc-
tion of enzymes involved in either degradation of particular
compounds in lysosomes or lysosomal transport [26]. There
are 50 or so known LSDs, which are grouped into severe and
progressive disorders.
MPSs (mucopolysaccharidoses) are classical examples of
LSD. Storage of GAGs (glycosaminoglycans) in cells of pati-
ents suffering from MPSs results in progressive damage of
the affected tissues, including the heart, respiratory system,
bones, joints and, in some cases, CNS (central nervous
system) [27]. Depending on the lacking or deficient enzyme
and kinds of accumulated GAGs, 11 types and subtypes of
MPS have been recognized [27]. Apart from MPS II, which
is an X chromosome-linked disease, all other MPS types are
inherited in an autosomal recessive manner. In most cases,
these diseases are fatal, with an average expected lifespan of
one or two decades.
Until 2003, no effective treatment was available for any
MPS type. Currently, ERT (enzyme-replacement therapy),
based on an intravenous infusion of an active recombinant
form of a deficient enzyme, can be used for treatment of
MPS I, MPS II and MPS VI [28]. This therapy is effective
in treatment of somatic symptoms. However, neurological
symptoms developed due to GAG accumulation in the CNS
cannot be managed by ERT owing to an inefficient delivery
of proteins through the BBB (blood–brain barrier). The CNS
dysfunction-related symptoms occur in some MPS I patients
(subtype MPS IH), most MPS II and MPS VII patients,
and all MPS III patients [27], where they are especially
severe.
Sanfilippo disease (MPS III) is a group of four conditions
(MPS III subtypes A, B, C and D), revealing similar clinical
symptoms and characterized by lysosomal storage of HS
(heparan sulfate), a GAG [27]. This condition is associated
with severe learning difficulties and behavioural disturbances,
and with relatively mild somatic involvement. In most
affected patients, the progressive nature of the disease leads
to death in the second (or rarely third) decade of life [27]. As
this disorder primarily affects the brain and nervous system,
attempts to cure the patients have not been successful, and
the best that can be offered is palliative or symptomatic
care.
An analysis of the regulation of metabolism of GAGs
has led to the suggestion that SRT (substrate-reduction
therapy), which is based on an impairment of production
of substrate(s) that cannot be degraded due to defects of
particular enzyme(s), might be an alternative solution
for patients suffering from MPSs, particularly from their
neuronopathic forms [29]. However, since GAGs are
synthesized frommonosaccharides (e.g. galactose, xylose,N-
acetylglucosamine and others) that are also involved in many
other biochemical pathways, a potential use of their analogues
as competitive inhibitors of certain synthetases might cause
defects in various biochemical reactions in cells and resultant
side effects in patients. It was therefore proposed that, in
the specific case of MPS, regulation of expression of genes
coding for particular enzymes required for GAG synthesis
might be a primary target for SRT rather than activities of
these enzymes [29].
Early observations have shown that maximum synthesis
of some GAGs requires either follicle-stimulating hormone
or EGF (epidermal growth factor) [30]. EGF influences
expression of certain genes by binding to its transmembrane
receptor that upon this interaction becomes an active protein
kinase, initiating a specific kinase cascade that finally results
in regulation of activity of particular transcription factors
(Figure 2). This tyrosine-specific protein kinase activity of
the EGFR (EGF receptor) is inhibited by genistein [31]. Thus
one might assume that, in the presence of genistein, GAG
synthesis might be impaired. Moreover, since this isoflavone
can cross the BBB to some extent [32], it was reasonable to
test whether addition of genistein may cause a reduction in
GAG production.
When genistein was present in the medium of cultured
human fibroblasts, it inhibitedGAG synthesis in cells ofMPS
I, MPS II, MPS IIIA and MPS IIIB patients (as measured by
incorporation of a radioactive precursor) [33]. This inhibition
has led to a decrease in lysosomal GAG storage, observed
after 1 week of incubation of fibroblasts with genistein at
concentrations between 10 and 30 μM (this was determined
biochemically, by measurement of actual intracellular GAG
levels, and in electron microscopic studies, by observa-
tions and counting of untypical intracellular structures)
[33].
Studies on themechanism of genistein-mediated inhibition
of GAG synthesis confirmed the theoretical prediction
[33] that the main regulatory pathway affected in this
biological system is the signal transduction pathway initiated
by the protein phosphorylation reaction stimulated by
EGF interaction with its receptor (Figure 2). Namely, an
excess of EGF abolished genistein-mediated impairment of
GAG synthesis in cultured fibroblasts, whereas increased
concentrations of genistein partially restored this negative
regulation [34].Moreover, genistein affectedEGFR-catalysed
phosphorylation efficiency [34]. These results, together with
the finding that efficiencyofGAGsynthesismay significantly
influence the severity of MPS diseases [35], support the
validity of the name proposed for the therapy based on the
use of genistein in MPS: GET IT (‘gene expression-targeted
isoflavone therapy’).
A recent pilot clinical study with ten patients suffering
from MPS IIIA and MPS IIIB indicated that genistin-rich
soya isoflavone extract, administered orally for 12 months at
the dose corresponding to 5 mg of genistein per 1 kg of body
weight daily, caused a statistically significant improvement
in all parameters tested [36]. Particularly, after 1 year of
therapy, urinary GAG levels were reduced, hair morphology
(assessed to be a useful parameter in monitoring efficacy of
C©The Authors Journal compilation C©2010 Biochemical Society
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Figure 2 A mechanism for genistein-mediated impairment of
expression of genes, whose products are involved in GAG
synthesis
Stimulation of expression of genes coding for enzymes required for
GAG production depends on EGF-mediated activation of its receptor,
EGFR. The EGFR tyrosine kinase (EGFR-TK) activity causes phosphorylation
of certain proteins involved in the cascade of kinases, which is the
process of transduction of intracellular signals, leading to activation of
transcription of speciﬁc genes in the nucleus. Inhibition of the EGFR-TK
activity by genistein (thick blunt-ended line) results in impairment of
the signal transduction and thus in a decreased expression of genes
coding for enzymes involved in GAG synthesis. Therefore the secondary
effect of this negative regulation is decreased efﬁciency of GAG
production.
treatment of patients suffering from various MPS types [37–
39]) improved, and patients achieved higher scores in the
psychological test that was constructed to measure cognitive
functions [36]. The last result is especially important as this
was the first report demonstrating an improvement of MPS
III patients after pharmacological treatment, and one of the
first, if not the first, direct indications that neurological
functions, already lost due to neurodegeneration in the
course of a disease, can be restored (at least partially) after
pharmacological treatment [40]. Moreover, an improvement
or stabilization in several non-quantified clinical parameters,
based on subjective assessments, was reported (Table 1) [36].
It isworth noting that, owing to a progressive character of this
disease, a gradual deterioration of most clinical parameters is
observed in untreated MPS III patients [27]. Importantly,
no significant side effects were observed during the GET
IT clinical study [36], which indicated that this treatment is
safe.
The encouraging findings described above have been
corroborated by recent results of studies on both cellular and
animal models of Sanfilippo disease, where either genistein or
another inhibitor of GAG synthesis, rhodamine B, were used
[41–43]. Furthermore, RNA interference-mediated specific
silencing of chosen genes coding for enzymes involved in
GAG synthesis resulted in inhibition of GAG production
[44,45], indicating that gene expression-targeted therapies
may be effective in treatment of MPS indeed. Thus further
clinical studies on the use of genistein in the treatment
of MPS III patients appear to be highly desired, and,
in fact, a double-blinded placebo-controlled clinical trial,
with the use of the soya isoflavone extract at the dose
corresponding to 10 mg of genistein per 1 kg of body weight
daily, has been initiated in June 2009 (F. Wijburg, personal
communication).
Since accumulation of GAGs also occurs in some other
LSDs (e.g. mucolipidoses, multiple sulfatase deficiency)
[26,27], it appears that further studies on the mechanisms
of LSDs and activities of genistein and other flavonoids
should be important in development of novel therapeutic
procedures for as yet non-treatable genetic diseases. One
might also consider that a combination of two (or more)
different therapies, for exampleERTandGETIT, canbemore
effective than any single therapy. It is particularly tempting to
speculate that such a combination may be especially suitable
for neuronopathic forms of MPS (e.g. MPS IH, severe forms
of MPS II), for which ERT is effective only in the treat-
ment of visceral organs. In fact, a combination of ERT and
HSCT (haemopoietic stem cell transplantation) was tested
recently as a therapy for MPS IH (Hurler’s syndrome) [46],
and we believe that it is reasonable to propose a combination
ofGET ITwith ERTorHSCTor both, whichmight improve
the efficacy of treatment of MPS.
Since in the pilot clinical study with GET IT for MPS III
a soya isoflavone extract was used rather than pure genistein
[36], a question appeared as towhether a natural source of this
isoflavone or a synthetic compound should be the final form
of the drug. In most soya extracts, genistein occurs in the
form of its glycoside, genistin. Since bioavailability of
genistein was reported to be higher than genistin in rats
[47], further clinical studies with pure genistein appear to
be required.
If we consider the use of isoflavone extracts, another ques-
tion regarding GET IT is the source of the biologically active
compound. Since various isoflavone-containing products are
commercially available, itwas crucial to determine their actual
composition and quality. A previous study has indicated that,
among products available in the U.S.A., actual content of
isoflavones was between 41 and 99% of that claimed by
manufacturers [48].Over 50-fold differences in total amounts
of isoflavones were found among various soya isoflavone
supplements and extracts tested in Western Europe [49].
A recent report describes extremely different amounts of
isoflavones determined in various products purchased in
Poland, from 0.13 to 39 mg per tablet, although amounts
declared by manufacturers were similar [50]. Moreover,
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Table 1 Effects of 1-year treatment of MPS III patients with genistein-rich soya isoﬂavone extract (at the dose of 5 mg/kg of body
weight per day) during the pilot clinical studies
Data taken from [36].
Patients revealing (after 1 year of treatment, relative to baseline)
Parameter Deterioration (%) Stabilization (%) Improvement (%)
Measured parameters*
Urinary GAG level 30 0 70
Hair morphology 0 20 80
Cognitive functions 0 20 80
Estimated parameters†
Speech performance 10 40 50
Speech comprehension 0 40 60
Activity 0 60 40
General behaviour 0 40 60
Sleep habits 0 30 70
Pain 0 90 10
Walking 20 40 40
Manual dexterity 0 60 40
Joint mobility 20 40 40
Breathing during day 0 80 20
Breathing at night 0 70 30
Infections 0 20 80
Hearing 0 70 30
Skin elasticity 10 30 60
Hair structure 10 10 80
Dyspeptic symptoms 0 50 50
Stools 10 10 80
*Values were measured using objective methods (biochemical assays, microscopic observations and psychological tests).
†Assessments were performed on the basis of subjective criteria (questionnaires and clinical observations).
only some of these products were found to be effective in
inhibition of synthesis of GAGs in cultured fibroblasts [50].
Therefore a careful choice of a proper isoflavone extract is
crucial for efficacy of GET IT.
Concluding remarks
Genistein, a natural isoflavone occurring in relatively large
amounts in some plants (e.g. soya), appeared to be an
effective therapeutic in inherited diseases, as different as
the most frequent fatal genetic disease in the Caucasian
population of U.S.A. and Europe, CF, and one of the
most severe genetic diseases, MPS. Although molecular
mechanisms of action of genistein in these two cases are
different, multiple biological activities of this isoflavonemake
it an attractive compound when a safe and effective treatment
of a complicated disease is considered. It appears that further
studies on: (i) optimization of genistein-based therapies
(particularly, optimization of the dose and the method of
application); (ii) artificial derivatives of genistein, which
might have even more desirable therapeutic properties; and
(iii) combination of the use of genistein (or its derivatives)
and other therapeutic methods may lead to development of
highly effective medical procedures, allowing the manage-
ment of as yet untreatable genetic diseases.
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